Literature DB >> 21946813

MicroRNA miR-548d is a superior regulator in pancreatic cancer.

Holger Heyn1, Sabine Schreek, Reena Buurman, Tim Focken, Brigitte Schlegelberger, Carmela Beger.   

Abstract

OBJECTIVES: This study aimed to identify microRNAs as novel biomarkers for improved diagnosis, prognosis prediction, and as a therapeutic target for pancreatic cancer. microRNAs may have a general role by acting as superordinated key regulators of tumorigenesis.
METHODS: Individual cellular molecules of multiple pathways associated with pancreatic cancer were analyzed for common microRNA binding sites, thereby enabling the identification of key regulating microRNAs. The potential of the identified microRNAs was subsequently determined in cell culture experiments.
RESULTS: Using bioinformatic pathway analyses, miR-548d was identified to target multiple components of pancreatic cancer-related pathways. The effect of microRNA on pancreatic cells was determined by overexpression studies using PANC-1 cells, resulting in impaired cell proliferation because of increased apoptosis and cell cycle arrest. In addition, miR-548d overexpression led to a sensitization to gemcitabine.
CONCLUSIONS: MicroRNA miR-548d was identified as a potential superior regulator for the development and progression of pancreatic cancer by targeting multiple factors of crucial pathways. Therapeutically, microRNAs with superordinate function, such as miR-548d, may be promising diagnostic and therapeutic tools for the future treatment of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21946813     DOI: 10.1097/MPA.0b013e318224b701

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  12 in total

1.  MAPK and JAK/STAT pathways targeted by miR-23a and miR-23b in prostate cancer: computational and in vitro approaches.

Authors:  Seyed Hamid Aghaee-Bakhtiari; Ehsan Arefian; Mahmood Naderi; Farshid Noorbakhsh; Vahideh Nodouzi; Mojgan Asgari; Pezhman Fard-Esfahani; Reza Mahdian; Masoud Soleimani
Journal:  Tumour Biol       Date:  2015-01-22

Review 2.  Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.

Authors:  V Taucher; H Mangge; J Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2016-04-08       Impact factor: 6.730

Review 3.  Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.

Authors:  Satyanarayana Rachagani; Muzafar A Macha; Nicholas Heimann; Parthasarathy Seshacharyulu; Dhanya Haridas; Seema Chugh; Surinder K Batra
Journal:  Adv Drug Deliv Rev       Date:  2014-10-23       Impact factor: 15.470

4.  miR-548d-3p inhibits the invasion and migration of gastric cancer cells by targeting GKN1.

Authors:  Senlong Yu; Hongjie Meng; Shengguang Shi; Shenghui Cao; Tianhua Bian; Haifeng Zhao
Journal:  J Clin Lab Anal       Date:  2022-06-06       Impact factor: 3.124

5.  A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.

Authors:  Tint Lwin; Xiaohong Zhao; Fengdong Cheng; Xinwei Zhang; Andy Huang; Bijal Shah; Yizhuo Zhang; Lynn C Moscinski; Yong Sung Choi; Alan P Kozikowski; James E Bradner; William S Dalton; Eduardo Sotomayor; Jianguo Tao
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

Review 6.  Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects.

Authors:  Daniel Neureiter; Tarkan Jäger; Matthias Ocker; Tobias Kiesslich
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

7.  Gene expression profiling analysis of castration-resistant prostate cancer.

Authors:  Xuelei Wang; Jiling Wen; Rongbing Li; Guangming Qiu; Lan Zhou; Xiaofei Wen
Journal:  Med Sci Monit       Date:  2015-01-16

8.  Assessment of acute pancreatitis severity via determination of serum levels of hsa-miR-126-5p and IL-6.

Authors:  Ying-Jie Chen; Tian-Lai Lin; Zhe Cai; Chang-Hu Yan; Sen-Ren Gou; Yao-Dong Zhuang
Journal:  Exp Ther Med       Date:  2020-11-09       Impact factor: 2.447

9.  microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer.

Authors:  Jack W Rostas; Hawley C Pruitt; Brandon J Metge; Aparna Mitra; Sarah K Bailey; Sejong Bae; Karan P Singh; Daniel J Devine; Donna L Dyess; William O Richards; J Allan Tucker; Lalita A Shevde; Rajeev S Samant
Journal:  Mol Cancer       Date:  2014-08-29       Impact factor: 27.401

10.  miR-548d-3p/TP53BP2 axis regulates the proliferation and apoptosis of breast cancer cells.

Authors:  Qiong Song; Jiangqiang Song; Qimin Wang; Yanling Ma; Nai Sun; Jieyu Ma; Qiu Chen; Guishan Xia; Yanping Huo; Longqiu Yang; Baolin Li
Journal:  Cancer Med       Date:  2015-12-13       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.